Published in Health Business Week, February 27th, 2009
OSI is currently reviewing the Notice Letter and has 45 days from the date of receipt to commence a patent infringement lawsuit against Teva and expects to file suit in that time frame. Tarceva is currently protected by three patents that are listed in the FDA’s Approved Drugs Products List (Orange Book). A lawsuit brought with respect...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.